CN105942501A - Tablets capable of increasing bone density and preparation method of tablets - Google Patents
Tablets capable of increasing bone density and preparation method of tablets Download PDFInfo
- Publication number
- CN105942501A CN105942501A CN201610294819.2A CN201610294819A CN105942501A CN 105942501 A CN105942501 A CN 105942501A CN 201610294819 A CN201610294819 A CN 201610294819A CN 105942501 A CN105942501 A CN 105942501A
- Authority
- CN
- China
- Prior art keywords
- fine powder
- tablets
- bone density
- preparation
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 48
- 230000001965 increasing effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 46
- 238000002156 mixing Methods 0.000 claims abstract description 41
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 38
- 102000008186 Collagen Human genes 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 30
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 25
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 25
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 23
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 22
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 claims abstract description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000007779 soft material Substances 0.000 claims abstract description 13
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 11
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 10
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 7
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 7
- 238000005469 granulation Methods 0.000 claims abstract description 4
- 230000003179 granulation Effects 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 66
- 239000002671 adjuvant Substances 0.000 claims description 27
- 239000011812 mixed powder Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 15
- 230000007704 transition Effects 0.000 claims description 14
- 230000008676 import Effects 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- 229960005188 collagen Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 abstract description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 2
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 38
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 30
- 239000011575 calcium Substances 0.000 description 30
- 229910052791 calcium Inorganic materials 0.000 description 30
- 230000000694 effects Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000002805 bone matrix Anatomy 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000013341 scale-up Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- CADZRPOVAQTAME-UHFFFAOYSA-L calcium;hydroxy phosphate Chemical compound [Ca+2].OOP([O-])([O-])=O CADZRPOVAQTAME-UHFFFAOYSA-L 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- -1 NAG glycosides Chemical class 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VSKBNXJTZZAEPH-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O VSKBNXJTZZAEPH-NSEZLWDYSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical class NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910001576 calcium mineral Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002910 structure generation Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses tablets capable of increasing bone density and a preparation method of the tablets. Every 1000 tablets contain raw materials including 210-220g of calcium carbonate, 190-200g of D-glucosamine sulfate, 20-30g of chondroitin sulfate, 80-85g of collagen, 0.10-0.20g of vitamin D3 and 3-8g of sodium hyaluronate, and auxiliary materials including 160-165g of microcrystalline cellulose and 5-10g of magnesium stearate. The preparation method comprises the following technological steps of crushing the raw materials and the auxiliary materials, performing screening, performing weighing, performing mixing, making soft materials, performing granulation, performing drying, performing size stabilization, performing integral mixing, performing tabletting, performing selection, performing packaging and the like. According to the tablets and the preparation method thereof disclosed by the invention, the D-glucosamine sulfate, the chondroitin sulfate, the collagen, the vitamin D3 and the sodium hyaluronate are used as main raw materials, the technology is simple, and the industrial production is facilitated; in addition, the dosage is accurate, the quality is stable, the tablets conform to the hygienic standard, the appearances of the tablets are clean and beautiful, the tablets are easy to accept by consumers, and the tablets are convenient to carry and transport.
Description
Technical field
The present invention relates to field of health care food, particularly relate to a kind of increase bone density sheet and preparation method thereof.
Background technology
Bone density refers to the number of bone mineral content in unit volume, and wherein calcium is the master of bone mineral
Wanting composition, calcium deposition in skeleton has directly effect to bone density.Doped calcium in skeleton
The most, bone density is the biggest, and skeleton is the most solid.And bone density and osteoporosis have contact closely,
Mid-aged population increases along with aging, bone conversion ratio, and bone resorption is more than bone formation, and bone amount reduces,
Bone density reduces, thus causes osteoporosis.How many bone density values is how to reflect osteoporosis degree
Important reference.Osteoporotic main harm is concurrently to fracture, and the incidence rate of fracture is along with bone
Mineral density reduces and progressively property increase.Current osteoporotic incidence rate in the trend risen year by year,
This has severely impacted the quality of life of middle-aged and elderly people.
Osteoporosis is ever-increasing health problem in world wide, and causes osteoporosis most important
A reason be exactly bone loss, the reduction of bone density.Along with being incremented by and prevention of aging populations
Consciousness enhancing, for osteoporosis exploitation health product substantially in ascendant trend year by year.From domestic closely
From the point of view of Nian Laiyi declares the health food situation with increase bone substance density improving function got off, it is broadly divided into two
Class a: class is calcic, is reached to increase the health food of bone density purpose by direct supplement calcium；
Another kind of it is free from calcium or not for the purpose of replenishing the calcium, but promotes the suction of calcium by adjusting endocrine
Receive thus reach to increase the health food of bone density this purpose.This two class has increase bone substance density improving function
Health food commercially achieve preferable repercussion and also occupies certain share simultaneously, but relatively
In the hugest adaptation population's quantity, have and increase the health food market of bone substance density improving function the most far away
Saturated, market development space is huge.
Although existing bone density sheet also can reach health-care effect, but the synergism between supplementary material
Low, bioavailability is relatively low, and nutrition is more single, and preparation method is relatively backward, and the bone of preparation is close
Degree tablet quality is not high enough.
Summary of the invention
For the problem of above-mentioned existence, increase bone density sheet and preparation side thereof it is desirable to provide a kind of
Method, this bone density sheet uses new formula compatibility, each element reasonable mixture ratio, has each other very
Important " working in coordination with " effect, advantageously in absorption and the utilization of nutrient, various raw material phase interworkings
Close, play the effect increasing bone density from many aspects, and the present invention is directed to this new formula and disclose
A kind of new preparation method, the bone density tablet quality using new preparation method to prepare is high, efficiency high system
Standby process environmental protection, pollution-free.
To achieve these goals, the technical solution adopted in the present invention is as follows:
A kind of bone density sheet that increases, every 1000 containing raw material: calcium carbonate 210-220g, D-amino Portugal
Grape sugar sulfate 190-200g, chondroitin sulfate 20-30g, collagen protein 80-85g, vitamin
D30.10-0.20g, hyaluronate sodium 3-8g；Adjuvant: microcrystalline Cellulose 160-165g, magnesium stearate
5-10g。
Most preferably scheme is: every 1000 containing raw material: calcium carbonate 215g, D-glucosamine
Sulfate 199g, chondroitin sulfate 25g, collagen protein 84g, vitamin D30.16g, transparent
Matter acid sodium 5g；Adjuvant: microcrystalline Cellulose 164.84g, magnesium stearate 7g.
Calcium carbonate: calcium is nutrient important in human body, is the premise bar maintaining skeleton strong
Part.Calcium in human body, nearly 99% is present in skeleton, the main structure of skeleton be bone matrix and
Bone cells.Bone matrix is formed by bone collagen fiber and calcium salt, and the two combination makes bone become
Hard and there is certain elasticity；If the growth that absorption calcium amount deficiency can affect body and skeleton is sent out
Educating, calcium content of bone declines, and bone density also reduces therewith.Research is it is believed that the calcium of q.s
Take in and increase bone density is had actively impact, pre-preventing bone rarefaction is had certain effect；Calcium carbonate
As a kind of traditional calcium source, calcium content is high, bioavailability preferably, have no side effect, be one
Plant the calcium source of less expensive..
Calcium carbonate quality standard: meet the regulation of GB1898 food additive calcium carbonate.
D-glucosamine sulfate: D-glucosamine sulfate as chitin,
Relative molecular mass is little, stable in properties.Chitin is natural degradable high molecular polymer, tool
There is special biological activity；The important catabolite of chitin include D-Glucosamine Hydrochloride,
D-glucosamine sulfate and 2-Acetamido-2-deoxy-D-glucose；If articular cartilage is destroyed, gesture
Bone density must be had influence on.Exogenous supplementary glucosamine sulfate compounds can promote cartilage
Cell regeneration.Modern pharmacological research shows, glucosamine has the physiology merit increasing bone density
Energy.
D-glucosamine sulfate quality standard:
Chondroitin sulfate: chondroitin sulfate (CS) belongs to polysaccharide, is a kind of biomacromolecule thing
Matter.Chondroitin sulfate, as the important component part of connective tissue, can promote bone growth, repair
Nutrition needed for multiple osseous tissue, supply osteogenesis, the metabolism of participation skeleton；Sulphuric acid
Chrondroitin has higher ion polarity, and this is for the active shadow of various cells in regulation osseous tissue
Ring calcium ion deposition in sclerotin significant；Chondroitin sulfate also has substantially simultaneously
Parent cartilage, can preferentially enter cartilaginous tissue, protect cartilage；Some can also be suppressed to damage close
The proteolytic enzyme of joint cartilage and lysosomal enzyme, such as Elastase, NAG glycosides enzyme etc.
Generation；Chondroitin sulfate has protection cartilage, promotes that osteocyte generates, and improves bone mineral content
Function with bone density.
Chondroitin sulfate quality standard:
Collagen protein: collagen protein is to be distributed the widest a kind of protein in human body, is mainly distributed
In the middle of connective tissue, it is a kind of functional protein relevant with tissue and organ dysfunction.Skeleton
Being the complicated organism being made up of bone matrix and bone mineral, bone matrix more than 90% composition is
Collagen, the main component of bone mineral is calcium hydroxy phosphate, and first the formation of skeleton be that collagen is fine
Dimension is interleaved with each other formation substrate net, and then calcium, phosphorus are deposited on collagen with the form of calcium hydroxy phosphate
In the space of substrate net, form skeleton.Collagen protein is the adhesive of calcium hydroxy phosphate, it with
Calcium hydroxy phosphate together constitutes the main body of skeleton, to maintaining the complete of bone structure and bone Biological Strength
Characteristic is extremely important, thus directly related with bone density change and bone metabolism；Supplement collagen egg
White systematicness and the fastness that just can increase structural rack, the calcium salt that such body is absorbed is
Can be deposited in an orderly manner in reticular system, be responsible for clinging calcareous, maintain the toughness of bone, increase bone
Density；Collagen protein has collage synthesis in reinforcement, promotes the mineral absorptions such as calcium, increases
Bone strength, promotes bone growth, strengthens the effect of bone density.
Collagen protein quality standard:
Vitamin D3: vitamin D is not only a kind of vitamin, is also a kind of hormone precursor.
Its main Physiological Function is the stable state maintaining alcium and phosphor metabolization, including assisting intestinal Calcium and phosphorous absorption,
Make mineralization of skeleton, reduce calcium and deposit in bone from renal excretion, promotion calcium, thus promote bone shape
Become.Owing to osteoblast and osteoclast also existing vitamin D simultaneously, so vitamin D
Dual regulation is played in the synthesis and catabolic process of bone, can promoting bone growing.
Vitamin D3Quality standard:
Hyaluronate sodium: hyaluronate sodium (HA) is the sodium-salt form of hyaluronic acid, and transparent
Matter acid is a kind of acid mucopolysaccharide, is widely present in animal body, and it has ideal as carrier
Physics and chemistry and biological characteristics, can be as multiple protein and the effective carrier of somatomedin.Simultaneously
HA is also to constitute articular cartilage and the main component of synovial fluid, has Saving cortilage cartilage, promotes to close
Save the ability of soft symphysis and regeneration.Research display, hyaluronate sodium can promote sarcoplast
Break up to osteoblast direction；Hyaluronate sodium is as a kind of biology economic, safe and effective
Preparation, its wide material sources, purification simplicity, affordable.Hyaluronate sodium has good life
The thing compatibility, has no side effect, can metabolism completely in vivo.Owing to it can be as multiple protein
Effective carrier, it can assist collagen protein effectively play increase bone density effect.Periodically
Exogenous supplementary hyaluronate sodium can significantly improve the content of internal hyaluronate sodium.
Hyaluronate sodium quality standard:
Microcrystalline Cellulose: filler, excipient.Microcrystalline Cellulose is the hydrolyzate of native cellulose,
White or off-white color, odorless, tasteless can free-pouring crystalline powder (micropartical of Non-fibrous).
Water insoluble, the acid of dilution and the organic solvent of majority, be slightly soluble in the aqueous slkali of 20%, stable in properties,
It it is a kind of conventional adjuvant.It is of many uses in terms of health food is used as adjuvant, main in this product
Filler to be done and excipient, addition is about 23.55%.This addition meets tabletting requirement, makes
Product appearance smooth completely, disintegration meets the requirements.
The quality standard quality of microcrystalline Cellulose should meet the Pharmacopoeia of the People's Republic of China 2015
The regulation of version four.
Magnesium stearate: lubricant.Magnesium stearate is the fine and smooth light powder of white, has good tack,
It is conventional hydrophobic lubricant, there is lubrication, anti-stick, fluidizer effect, frequently as capsule, sheet
The lubricant of agent.In " pharmacy of Chinese materia medica " of Fan Biting chief editor, its amount of recommending is 0.25%～1%.
In this product, the usage amount of magnesium stearate is 1.00%.The mixture good fluidity obtained, can press smoothly
Sheet, sticking, consumption be not suitable.
The quality standard quality of magnesium stearate should meet the Pharmacopoeia of the People's Republic of China 2015 editions
The regulation of four.
A kind of preparation method increasing bone density sheet, comprises the following steps:
S1 pulverize, sieve: by calcium carbonate, D-glucosamine sulfate, chondroitin sulfate,
Collagen protein, hyaluronate sodium are pulverized respectively, cross 60,80,100 mesh mesh screens successively and carry out three
Level screening, obtains fine powder, vitamin D3, microcrystalline Cellulose successively cross 80,100,120 mesh sieves obtain
Fine powder, standby；
S2 weighs: weigh calcium carbonate fine powder, D-glucosamine sulfate respectively by formula proportion
Fine powder, chondroitin sulfate fine powder, collagen protein fine powder, vitamin D3Fine powder, hyaluronate sodium
Fine powder, microcrystalline Cellulose fine powder, magnesium stearate, standby；
S3 mixes: by vitamin D3Fine powder, hyaluronate sodium fine powder equal increments method mixes,
I.e. take vitamin D3Fine powder mixes with the hyaluronate sodium fine powder of equivalent, after mix homogeneously, by institute
Obtain mixed powder to mix with the hyaluronate sodium fine powder of equivalent, mix homogeneously, repeat this process, directly
To by complete for the mixing of all hyaluronate sodium fine powders, obtain mixed powder 1；By soft with sulphuric acid for mixed powder 1
Ossein fine powder mixing 8-10min, obtains mixed powder 2；Mixed powder 2 is mixed with collagen protein fine powder
8-10min, obtains mixed powder 3；Again by mixed powder 3 and calcium carbonate fine powder, the D-amino Portugal of gained
Grape sugar sulfate fine powder, microcrystalline Cellulose fine powder mixing 25-30min, obtain mixed powder 4；
S4 soft material: the purified water of 8-10 DEG C is added in mixed powder 4, soft material processed, obtain soft material；
S5 pelletizes: soft material is crossed 16 mesh, 18 mesh, 20 mesh mesh screens granulations respectively, obtains wet granular；
S6 is dried, granulate: is dried 3-4h under the conditions of 50-55 DEG C, treats temperature in dry run
After being increased to 50 DEG C, from the beginning of 50 DEG C, temperature raises 1 DEG C at intervals of two minutes, and temperature is increased to
Heat preservation and dryness when 55 DEG C, to water content≤5%, crosses 16,18,20 mesh and carries out three level screen granulate,
Granule must be done；
S7 always mixes: load weighted magnesium stearate mixed homogeneously with dry granule mixing 8-10min,
Obtain total mixture；
S8 tabletting: by total mixture tabletting, obtaining tablet is 0.7g/ sheet；
S9 selects, inner packing, outer package and quality inspection, warehouse-in.
Further improvement of the present invention is: all use V-type batch mixing to set in described step S3, S7
Standby mixing, on the tank body of described V-type mixing equipment, to arrange at least one auxiliary in centre position
Material import.
Further improvement of the present invention is: each described adjuvant import is regular hexagon structure,
It is equipped with in described regular hexagon structure and the regular hexagon of described V-type mixing equipment one
Magnet frame, and arrange corresponding close with described regular hexagon Magnet frame on described V-type mixing equipment
Close the movable disk closed, described movable disk is arranged attracting just with described regular hexagon Magnet frame
Hexagon clamping is protruding.
Further improvement of the present invention is: also set up transition funnel above described adjuvant import,
At the feed opening of described transition funnel, feed hose is set.
Further improvement of the present invention is: arrange in described feed hose and described transition funnel
Quantifier, and vicarious valve is set on described transition funnel.
Further improvement of the present invention is: use drying equipment to be dried in described step S6,
Being provided with breather line inside described drying equipment, described breather line is distributed on circular air-spreading disk,
Each breather line is tightly connected with outside aeration equipment.
The invention has the beneficial effects as follows: compared with prior art,
One: preferably calcium carbonate, D-glucosamine sulfate, chondroitin sulfate, collagen protein,
Vitamin D3, hyaluronate sodium be primary raw material, various raw materials cooperate, and play increasing from many aspects
Add the effect of bone density.It addition, each materials safety of this product and dosage are all in the range of safety using amount,
Taking safety, this product is tablet simultaneously, and dosage is accurate, taking convenience, it is easy to selected by consumer
Accept.Increase bone density health care definite, suitable long-term taking；
Its two: this bone density sheet prepared according to formula and the preparation method of the present invention can supplement skeleton
Necessary calcium mineral and trace element, promote calcium absorption in skeleton and deposition.Rush is provided simultaneously
Enter bone cell proliferation and safeguard the nutrient substance of normal bone structure, maintaining normal osteogenesis and bone metabolism
Balance.Various raw materials cooperate, and play the effect increasing bone density from many aspects；
Its three: the present invention uses the feed way of property to be stage by stage added in order, it is possible to make major ingredient
Be more fully mixed, the assosting effect of adjuvant becomes apparent from；
Its four: in order to improve compounding effect, therefore use V-type mixing equipment, and in order to improve adjuvant
Add in order and charging efficiency, therefore on V-type mixing equipment, also set up the adjuvant import dress of automatic open-close
Put, so can the saving manpower of relatively limits, improve charging efficiency, and charging can also be carried out
Monitoring, convenient control feeds；
Its five: in order to improve drying effect in dry run, in drying equipment by ventilation, this
Sample can improve hot gas diffusion velocity in drying equipment, and the gas being passed through by breather line
Body can also carry out rolling stirring to wet granular, it is achieved being dried of each face of wet granular so that wet granular
It is dried the most thorough, it is simple to deposit for a long time.
Accompanying drawing explanation
Fig. 1 is present invention process flow chart.
Fig. 2 is V-type mixing equipment structural representation of the present invention.
Fig. 3 is the schematic diagram of circle air-spreading disk of the present invention.
Wherein: 1-mixing machine, 2-adjuvant import, 3-regular hexagon Magnet frame, 4-movable disk, 5-regular hexagon
Clamping is protruding, 6-transition funnel, 7-feed hose, 8-sealing ring, 9-suspension ring, 10-suspension hook, 11-
Circular air-spreading disk, 12-breather line.
Detailed description of the invention
In order to make those of ordinary skill in the art be better understood on technical scheme, below
In conjunction with the accompanying drawings and embodiments technical scheme is further described.
It is characterized in that, every 1000 containing raw material: calcium carbonate 210-220g, D-glucosamine sulfur
Hydrochlorate 190-200g, chondroitin sulfate 20-30g, collagen protein 80-85g, vitamin D30.10-0.20g、
Hyaluronate sodium 3-8g；Adjuvant: microcrystalline Cellulose 160-165g, magnesium stearate 5-10g.
Embodiment one: a kind of bone density sheet that increases, every 1000 containing raw material: calcium carbonate 215g, D-
Glucosamine sulphate 199g, chondroitin sulfate 25g, collagen protein 84g, vitamin D30.16g、
Hyaluronate sodium 5g；Adjuvant: microcrystalline Cellulose 164.84g, magnesium stearate 7g.
Install to inner packing production process from supplementary material removing outsourcing all carry out in 300,000 grades of clean areas.
A kind of preparation method increasing bone density sheet, comprises the following steps:
S1 pulverize, sieve: by calcium carbonate, D-glucosamine sulfate, chondroitin sulfate,
Collagen protein, hyaluronate sodium are pulverized respectively, cross 60,80,100 mesh mesh screens successively and carry out three
Level screening, obtains fine powder, vitamin D3, microcrystalline Cellulose successively cross 80,100,120 mesh sieves obtain
Fine powder, standby；
S2 weighs: weigh calcium carbonate fine powder, D-glucosamine sulfate respectively by formula proportion
Fine powder, chondroitin sulfate fine powder, collagen protein fine powder, vitamin D3Fine powder, hyaluronate sodium
Fine powder, microcrystalline Cellulose fine powder, magnesium stearate, standby；
S3 mixes: by vitamin D3Fine powder, hyaluronate sodium fine powder equal increments method mixes,
I.e. take vitamin D3Fine powder mixes with the hyaluronate sodium fine powder of equivalent, after mix homogeneously, by institute
Obtain mixed powder to mix with the hyaluronate sodium fine powder of equivalent, mix homogeneously, repeat this process, directly
To by complete for the mixing of all hyaluronate sodium fine powders, obtain mixed powder 1；By soft with sulphuric acid for mixed powder 1
Ossein fine powder mixing 8-10min, obtains mixed powder 2；Mixed powder 2 is mixed with collagen protein fine powder
8-10min, obtains mixed powder 3；Again by mixed powder 3 and calcium carbonate fine powder, the D-amino Portugal of gained
Grape sugar sulfate fine powder, microcrystalline Cellulose fine powder mixing 25-30min, obtain mixed powder 4；
Mixed powder 3 and calcium carbonate fine powder, D-glucosamine sulfate fine powder, microcrystalline Cellulose
During fine powder mixing 30min, be respectively 1.16% from the diverse location hydroxyproline content that records of sampling,
1.13%, 1.17%, 1.15%, 1.19%, 1.22%, RSD ＜ 5%；
During mixing 25-30min, sample significant component content difference ＜ recorded from diverse location
5%, show mix homogeneously and preferably, in conjunction with production cost and cycle, finally determine incorporation time
For 25-30min；
S4 soft material: the purified water of 8-10 DEG C is added in mixed powder 4, soft material processed, obtain soft material；
S5 pelletizes: soft material is crossed 16 mesh, 18 mesh, 20 mesh mesh screens granulations respectively, obtains wet granular；
S6 is dried, granulate: is dried 3-4h under the conditions of 50-55 DEG C, treats temperature in dry run
After being increased to 50 DEG C, from the beginning of 50 DEG C, temperature raises 1 DEG C at intervals of two minutes, and temperature is increased to
Heat preservation and dryness when 55 DEG C, this process uses gradually formula heating mode, in such wet granular
Structure has a process gradually absorbed, and in being unlikely to cause it due to unexpected intensification
The change of portion's crystal structure generation microcosmic, therefore use this kind of mode to carry out gradually formula and heat up, it is possible to
Be greatly improved the drying effect of product, be dried from outside to inside, be dried thorough, to water content≤
5%, cross 16,18,20 mesh and carry out three level screen granulate, obtain dry granule；
S7 always mixes: load weighted magnesium stearate mixed homogeneously with dry granule mixing 8-10min,
Obtain total mixture；
Angle of repose measures:
Using solid funnel method, by 3 funnel series connection, the end opening of lowest funnel is away from horizontal positioned
Graph paper 1.5cm height (H) place, carefully material is poured in the funnel of the superiors along funnel,
Until forming material cone tips on graph paper to touch nethermost funnel end opening, by
Graph paper is measured the diameter (2R) of conical base and is calculated angle of repose (tg α=H/R)；Take 3 parts
Total mixture, records α angle of repose and is respectively 37 °, 36 °, 37 °；Visible total mixture
Mobility is preferable, can be with direct compression；
S8 tabletting: using high speed tablet press to carry out tabletting, by total mixture tabletting, obtaining tablet is
0.7g/ sheet；
S9 selects, and rejects defective；Inner packing, 40 slices/bottle, inner packaging material meets
The standard of YBB00122002 oral stable medicinal polythene bottle with high density；Outer package, outer package
The standard of GB/T6543 single and double corrugated boxes for transport packages is met with carton；With
And quality inspection, warehouse-in；
Further improvement of the present invention is: all use V-type batch mixing to set in described step S3, S7
For mixing, shown in accompanying drawing 2-3, middle on the tank body of described V-type mixing equipment
Position arranges four adjuvant imports 2, before this adjuvant import 2 is separately positioned on two mixing machines 1
On trailing flank；Each described adjuvant import 2 is regular hexagon structure, at described regular hexagon
It is equipped with in structure and the regular hexagon Magnet frame 3 of described V-type mixing equipment one, and
Work with the corresponding seal closure of described regular hexagon Magnet frame 3 is set on described V-type mixing equipment
Moving plate 4, movable disk 4 is movably connected on V-type mixing equipment by movable axis, V-type batch mixing
The closing face center of equipment arranges the irony material matched with described regular hexagon Magnet frame 3
The regular hexagon clamping projection 5 that material is made, also sets up transition funnel above described adjuvant import 2
6, at the feed opening of described transition funnel 6, feed hose 7 is set；In order to improve preparation method
Efficiency and prepare the quality of finished product, therefore centre position is arranged on the tank body of V-type mixing equipment
Four adjuvant imports 2, during charging, quantitative adjuvant blanking from transition funnel 6 of weighing, and lead to
Cross feed hose 7 to feed, it is therefore prevented that in fill process, adjuvant is infected by introduced contaminants,
Transition funnel 6 arranges the protective enclosure of environment-friendly type, adjuvant is hedged off from the outer world, fed
Cheng Hou, clamping projection and regular hexagon fast automatic tightly the holding of Magnet frame 3, complete automatically
Folding, the surrounding protruding in clamping also sets up a circle sealing ring 8, it is ensured that V-type mixing equipment
Seal, in order to further improve closure effect, arranges suspension hook on the edge of movable disk 4
10, and arrange on V-type mixing equipment and the suspension ring 9 of suspension hook 10 hanging, form dual Guan Bi
System, can not only realize conveniently feeding by the setting of said structure, saves manpower, and
Adjuvant can also be protected, it is achieved feeding in order；It addition, described feed hose and described mistake
Cross and funnel arranges quantifier, and vicarious valve is set on described transition funnel, in charging
During, open vicarious valve, transition funnel blanking simultaneously, quantifier is weighed, and blanking is complete
Bi Hou, vicarious valve closes valve immediately, and adjuvant automatic blanking is complete, and automaticity is high,
Blanking is accurate.
Further improvement of the present invention is: use drying equipment to be dried in described step S6,
Being provided with breather line 12 inside described drying equipment, described breather line 12 is distributed in circular gas distribution
On dish 11, each breather line 12 is tightly connected with outside aeration equipment, in dry run is
Raising drying effect, by ventilation in drying equipment, so can improve hot gas and set being dried
Diffusion velocity in Bei, and wet granular can also be turned over by the gas being passed through by breather line 12
Rolling stirring, it is achieved being dried of each face of wet granular so that being dried of wet granular is more thorough, this
Bright technical scheme drying steps required time for as 3-4 hour, and needed 6-8 the drying time of prior art
Hour, hence it is evident that the time being dried after using technical scheme shortens.
Scale up test is verified
Table one: inventory expands 60 times, 60 times, 60 times according to formula ratio respectively, carries out three groups and puts down
Row enlarged experiment is tested, and result is as follows:
Table two: first parallel test product scale up test survey report
Table three: second batch parallel test product scale up test survey report
Four: the three batches of parallel test product scale up test survey reports of table
This formula for a product is based on calcium carbonate, and nutrient important during wherein calcium is human body, is to constitute
The important minerals of skeleton, is the precondition maintaining skeleton strong.And calcium intake deficiency can cause
Bone calcium reduces, and bone density declines.Experimental results demonstrate and take the effective supplement calcium of calcium energy, improve bone
Calcium content in bone, thus increase bone density.With D-glucosamine sulfate, chondroitin sulfate, glue
Former albumen is auxiliary.Glucosamine is the natural constituent of glycoprotein in human bone joint, can suppress
The activity of collagen hydro enzyme, can promote union of fracture promotive factor bone morphogenetic protein (BMP)
Secretion, makes mesenchymal cell convert to chondroblast and osteoblast, thus has increase bone density
Effect.Chondroitin sulfate, as the important component part of connective tissue, can promote bone growth, repair
Nutrition needed for multiple osseous tissue, supply osteogenesis, the metabolism of participation skeleton.It is widely present in people
With in animal cartilage tissue, its function protected to osseous tissue, osteoblast proliferation and new bone can be promoted
Formed, there is the effect increasing bone density.Collagen protein is the important component part of bone matrix, sufficient
Collagen protein can maintain bone matrix normal morphology and micro structure, strengthen the toughness of bone, promote calcium
Absorption and the precipitation in skeleton, keep bone health.It is equipped with vitamin D3 and hyaluronate sodium again.
The main Physiological Function of vitamin D is the stable state maintaining alcium and phosphor metabolization, including assisting intestinal Calcium and phosphorous absorption,
Making the appropriate mineralising of skeleton, minimizing calcium is from renal excretion, thus reduces the loss of bone amount.It is at bone simultaneously
Synthesis and catabolic process in play dual regulation, can promoting bone growing thus to increase bone close
Degree.Hyaluronate sodium is widely present in animal body, and it has preferable physics and chemistry and biology as carrier
Learn characteristic, can be as multiple protein and the effective carrier of somatomedin.HA is also to constitute articular cartilage
With the main component of synovial fluid, there is Saving cortilage cartilage, promote the healing of articular cartilage and the energy of regeneration
Power.Several raw materials cooperate, and can be effectively increased bone density, strong skeleton.
Verifying through three batches of scale up test and correlation test, the product indices that process above prepares all accords with
Close related request, so technique is reasonable.
Claims (8)
1. one kind increases bone density sheet, it is characterised in that every 1000 containing raw material: calcium carbonate 210-220g,
D-glucosamine sulfate 190-200g, chondroitin sulfate 20-30g, collagen protein 80-85g, dimension
Raw element D30.10-0.20g, hyaluronate sodium 3-8g；Adjuvant: microcrystalline Cellulose 160-165g, tristearin
Acid magnesium 5-10g.
A kind of increase bone density sheet the most according to claim 1, it is characterised in that every 1000 contain
Raw material: calcium carbonate 215g, D-glucosamine sulfate 199g, chondroitin sulfate 25g, collagen egg
White 84g, vitamin D3 0.16g, hyaluronate sodium 5g；Adjuvant: microcrystalline Cellulose 164.84g, hard
Fatty acid magnesium 7g.
3. the preparation method increasing bone density sheet, it is characterised in that comprise the following steps:
S1 pulverizes, sieves: by calcium carbonate, D-glucosamine sulfate, chondroitin sulfate, collagen egg
In vain, hyaluronate sodium pulverize respectively, successively cross 60,80,100 mesh mesh screens carry out three level screen,
Fine powder, vitamin D3, microcrystalline Cellulose are crossed 80,100,120 mesh sieves successively and are obtained fine powder, standby；
S2 weigh: weigh respectively by formula proportion calcium carbonate fine powder, D-glucosamine sulfate fine powder,
Chondroitin sulfate fine powder, collagen protein fine powder, vitamin D3 fine powder, hyaluronate sodium fine powder, micro-
Crystalline cellulose fine powder, magnesium stearate, standby；
S3 mixes: vitamin D3 fine powder, hyaluronate sodium fine powder equal increments method is mixed, i.e. takes dimension
Raw element D3 fine powder mixes with the hyaluronate sodium fine powder of equivalent, after mix homogeneously, by gained mixed powder
Mix with the hyaluronate sodium fine powder of equivalent, mix homogeneously, repeat this process, until by all transparent
The mixing of matter acid sodium fine powder is complete, obtains mixed powder 1；Mixed powder 1 is mixed with chondroitin sulfate fine powder
8-10min, obtains mixed powder 2；By mixed powder 2 and collagen protein fine powder mixing 8-10min, obtain mixing
Powder 3；Again by the mixed powder 3 of gained and calcium carbonate fine powder, D-glucosamine sulfate fine powder, micro-
Crystalline cellulose fine powder mixing 25-30min, obtains mixed powder 4；
S4 soft material: the purified water of 8-10 DEG C is added in mixed powder 4, soft material processed, obtain soft material；
S5 pelletizes: soft material is crossed 16 mesh, 18 mesh, 20 mesh mesh screens granulations respectively, obtains wet granular；
S6 is dried, granulate: is dried 3-4h under the conditions of 50-55 DEG C, treats that temperature is increased to 50 DEG C in dry run
After, from the beginning of 50 DEG C, temperature raises 1 DEG C at intervals of two minutes, and temperature is increased to heat preservation and dryness when 55 DEG C,
To water content≤5%, cross 16,18,20 mesh and carry out three level screen granulate, obtain dry granule；
S7 always mixes: load weighted magnesium stearate is mixed homogeneously with dry granule mixing 8-10min, obtains and always mix
Thing；
S8 tabletting: by total mixture tabletting, obtaining tablet is 0.7g/ sheet；
S9 selects, inner packing, outer package and quality inspection, warehouse-in.
A kind of preparation method increasing bone density sheet the most according to claim 3, it is characterised in that
Described step S3, S7 all use V-type mixing equipment mix, at described V-type mixing equipment
Tank body on centre position at least one adjuvant import is set.
A kind of preparation method increasing bone density sheet the most according to claim 4, it is characterised in that
Each described adjuvant import is regular hexagon structure, be equipped with in described regular hexagon structure with
The regular hexagon Magnet frame of described V-type mixing equipment one, and set on described V-type mixing equipment
Put and the movable disk of the described regular hexagon corresponding seal closure of Magnet frame, described movable disk is arranged and institute
State the attracting regular hexagon clamping of regular hexagon Magnet frame protruding.
A kind of preparation method increasing bone density sheet the most according to claim 5, it is characterised in that
Above described adjuvant import, also set up transition funnel, at the feed opening of described transition funnel, charging is set
Flexible pipe.
A kind of preparation method increasing bone density sheet the most according to claim 6, it is characterised in that
Described feed hose and described transition funnel arrange quantifier, and sense is set on described transition funnel
Answer formula valve.
8. according to a kind of preparation method increasing bone density sheet described in any one of claim 3-7, its feature
It is, described step S6 uses drying equipment be dried, be provided with inside described drying equipment
Breather line, described breather line is distributed on circular air-spreading disk, and each breather line leads to outside
Gas equipment is tightly connected.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610294819.2A CN105942501A (en) | 2016-05-03 | 2016-05-03 | Tablets capable of increasing bone density and preparation method of tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610294819.2A CN105942501A (en) | 2016-05-03 | 2016-05-03 | Tablets capable of increasing bone density and preparation method of tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105942501A true CN105942501A (en) | 2016-09-21 |
Family
ID=56914674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610294819.2A Pending CN105942501A (en) | 2016-05-03 | 2016-05-03 | Tablets capable of increasing bone density and preparation method of tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105942501A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065367A (en) * | 2017-12-13 | 2018-05-25 | 上海锐因生物科技有限公司 | It is a kind of for composition of joint care and preparation method thereof |
| CN108619493A (en) * | 2018-06-19 | 2018-10-09 | 国医健食（北京）科技有限公司 | A kind of capsule increasing bone density |
| CN108902987A (en) * | 2018-06-19 | 2018-11-30 | 北京中健天行医药科技有限公司 | Newborn mineral salt ammonia sugar chondroitin ties up D capsule |
| CN115191602A (en) * | 2022-05-16 | 2022-10-18 | 张司晨 | Food formula for improving content of 'high molecular weight hyaluronic acid' in vivo |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102894372A (en) * | 2012-11-05 | 2013-01-30 | 江苏江大源生态生物科技有限公司 | Health-care food for increasing bone density and preparation method thereof |
| CN103735572A (en) * | 2012-10-17 | 2014-04-23 | 山东明仁福瑞达制药股份有限公司 | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
| CN104382005A (en) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | Glucosamine chondroitin collagen tablet and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
| CN105318673A (en) * | 2015-11-13 | 2016-02-10 | 雅安市雨城区晏场鹿井茶厂 | Sectional type tea drying equipment |
-
2016
- 2016-05-03 CN CN201610294819.2A patent/CN105942501A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103735572A (en) * | 2012-10-17 | 2014-04-23 | 山东明仁福瑞达制药股份有限公司 | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition |
| CN102894372A (en) * | 2012-11-05 | 2013-01-30 | 江苏江大源生态生物科技有限公司 | Health-care food for increasing bone density and preparation method thereof |
| CN104382005A (en) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | Glucosamine chondroitin collagen tablet and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
| CN105318673A (en) * | 2015-11-13 | 2016-02-10 | 雅安市雨城区晏场鹿井茶厂 | Sectional type tea drying equipment |
Non-Patent Citations (4)
| Title |
|---|
| 化工部化工设计公司标准组: "《工业密封技术》", 31 May 1988, 化学工业出版社 * |
| 国家中医药管理局职业技能鉴定指导中心等: "《中药固体制剂工》", 30 November 2009, 中国中医药出版社 * |
| 张绪峤: "《药物制剂设备与车间工艺设计》", 31 July 2000, 中国医药科技出版社 * |
| 西北轻工业学院等: "《造纸装置及其防护》", 28 February 1981, 轻工业出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065367A (en) * | 2017-12-13 | 2018-05-25 | 上海锐因生物科技有限公司 | It is a kind of for composition of joint care and preparation method thereof |
| CN108619493A (en) * | 2018-06-19 | 2018-10-09 | 国医健食（北京）科技有限公司 | A kind of capsule increasing bone density |
| CN108902987A (en) * | 2018-06-19 | 2018-11-30 | 北京中健天行医药科技有限公司 | Newborn mineral salt ammonia sugar chondroitin ties up D capsule |
| CN115191602A (en) * | 2022-05-16 | 2022-10-18 | 张司晨 | Food formula for improving content of 'high molecular weight hyaluronic acid' in vivo |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105942501A (en) | Tablets capable of increasing bone density and preparation method of tablets | |
| CN105942500B (en) | Selenium-rich yeast tablet and preparation method thereof | |
| CN102224896B (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| CN101438764B (en) | Organic composite biological feed and method for producing the same | |
| CN100546462C (en) | Culture base-material of a kind of cultivating agaricus bisporus by using moss slag and preparation method thereof | |
| CN106306462A (en) | Probiotic fermented feed additive for pigs | |
| CN101406263A (en) | Feed formula for pig | |
| CN101671374B (en) | New technique for extracting D-glucosamine hydrochloride | |
| CN103609858A (en) | Feed additive and preparation method thereof | |
| CN102949710A (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN102551045A (en) | Collagen calcium tablet | |
| CN102919296A (en) | Nutritional wheat flour and production method thereof | |
| CN101856369A (en) | Stachyose tablets for calcium supplementation and intestinal micro-ecological regulation | |
| CN101803685B (en) | Preparation method of maggot biological protein powder and application thereof in feedstuff for live pigs | |
| CN103621776B (en) | A kind of Multifunctional Chinese medicine puffing aquatic product feed and preparation method thereof | |
| CN104687054A (en) | Nanoscale calcium health food and preparation method thereof | |
| CN101961482A (en) | Immunity enhancer for aquatic animals | |
| CN101732396A (en) | Method for preparing cucumber seed fermented material | |
| CN103588550A (en) | Production method of cultivation material of agaricus blazei murill | |
| CN103053902B (en) | A compound tablet with a high content of chondroitin sulfate and a preparation method thereof | |
| CN101851259A (en) | Selenium chitosan oligosaccharide and preparation method thereof | |
| CN104738623A (en) | Lentinus edodes powder capsules rich in vitamin K2 and calcium and preparation method thereof | |
| CN103609935B (en) | A kind of dietary supplement preventing middle-aged and old bone and joint diseases | |
| CN103203012A (en) | Joint health care product | |
| CN105440088A (en) | Glucosamine mixed strontium salt as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |